In a landmark decision for pediatric medicine, the U.S. Food and Drug Administration (FDA) has approved Kresladi (marnetegragene autotemcel), marking the first-ever approved gene therapy for the treatment of severe leukocyte adhesion deficiency type I (LAD-I). Approved on March 26, 2026, this therapy offers a critical recent lifeline for children born with a rare genetic disorder that severely compromises their immune systems FDA approval announcement.
Severe leukocyte adhesion deficiency type I is a devastating rare disease that prevents white blood cells from functioning normally. Without the ability to move from the bloodstream into tissues to fight infection, affected children are left susceptible to recurrent, life-threatening bacterial and fungal infections. For many, the prognosis without intervention is grim, as survival beyond childhood is rare UCLA news release.
The approval of Kresladi, manufactured by Rocket Pharmaceuticals, Inc., represents a significant shift in how medical professionals approach this rare immune disorder. By utilizing the FDA’s accelerated approval pathway, the therapy provides an alternative for pediatric patients who lack a human leukocyte antigen (HLA)-matched sibling donor for a traditional allogeneic hematopoietic stem cell transplant FDA Kresladi product page.
Understanding Severe Leukocyte Adhesion Deficiency Type I
LAD-I is an exceptionally rare genetic condition affecting approximately one in one million children globally. The disease is rooted in mutations of the ITGB2 gene, which are responsible for disrupting the normal function of two critical proteins: CD11 and CD18. These proteins must work in tandem to enable white blood cells to reach and respond to sites of infection in the body UCLA news release.
When these proteins fail to function, the body’s primary defense mechanism is effectively paralyzed. While the body may produce white blood cells, those cells cannot “adhere” to the blood vessel walls or migrate into the infected tissue. This breakdown in the immune response leads to severe, recurrent infections that can be fatal if not managed with aggressive medical intervention.
How Kresladi Works: A New Genetic Blueprint
Unlike traditional treatments that rely on finding a compatible donor, Kresladi is an autologous gene therapy. In other words the treatment uses the patient’s own cells to cure the disease. The process involves extracting the patient’s blood stem cells and adding a healthy copy of the ITGB2 gene to them. These modified cells are then returned to the patient, allowing their body to produce functional white blood cells capable of fighting infection UCLA news release.
This approach eliminates the primary risk associated with allogeneic transplants: the need for a perfectly matched donor and the subsequent risk of graft-versus-host disease. By using the patient’s own genetic material, the therapy aims to restore the immune system’s natural ability to protect the child from life-threatening pathogens.
The Path to Approval and Clinical Success
The development of Kresladi is the result of over 30 years of research into rare pediatric immune disorders. A pivotal role was played by Dr. Donald Kohn at UCLA, whose clinical trials provided the essential data for the FDA’s approval. The therapy was approved via the accelerated pathway, a mechanism designed to bring critical treatments to patients with serious conditions faster when existing options are limited UCLA news release.
Evidence of the therapy’s success was detailed in a study published in the New England Journal of Medicine in April 2025. Dr. Kohn’s phase 1-2 trial reported sustained efficacy and safety for all treated patients over a two-year period, demonstrating that the gene therapy could provide long-term stability for children who previously had very few options.
Patient Eligibility and Indications
Kresladi is not intended for all patients with immune deficiencies. The FDA has specifically indicated the therapy for pediatric patients who meet the following criteria:
- Diagnosis of severe leukocyte adhesion deficiency-I (LAD-I).
- Presence of biallelic variants in the ITGB2 gene.
- Lack of an available human leukocyte antigen (HLA)-matched sibling donor for an allogeneic hematopoietic stem cell transplant FDA Kresladi product page.
By targeting this specific group, the therapy addresses the most vulnerable population—those for whom the gold-standard transplant is not an option due to the lack of a matched sibling.
Key Takeaways for Families and Providers
| Detail | Information |
|---|---|
| FDA Approval Date | March 26, 2026 |
| Manufacturer | Rocket Pharmaceuticals, Inc. |
| Primary Target | Pediatric patients with LAD-I (ITGB2 variants) |
| Mechanism | Autologous gene therapy (patient’s own stem cells) |
| Approval Pathway | Accelerated Approval |
The approval of Kresladi is more than just a win for the few children affected by LAD-I; it serves as a blueprint for the development and commercialization of therapies for other ultra-rare genetic diseases. As we move forward, the success of this “patient-as-their-own-donor” model may pave the way for treating various other pediatric immune disorders that currently lack viable cures.
For the most current official guidance, clinicians and caregivers are encouraged to review the full package insert and supporting documents available on the official FDA website FDA Kresladi documentation.
As this therapy begins to reach patients globally, medical communities will be monitoring long-term outcomes to further validate the sustained efficacy seen in the initial trials. We will provide updates as more real-world data becomes available.
Do you have questions about the latest advancements in gene therapy? Share your thoughts in the comments below or share this article with others who may find this information vital.